Ding, C., Ma, L., Liang, Y., Zhang, Z., Wu, Q., Lyu, J., Su, L. (2025). Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system. Scientific Reports. https://doi.org/10.1038/s41598-025-99773-4